Apatinib as First -Line Treatment for Advanced Esophagus Cancer

Advanced Esophagus Cancer Clinical Trial

Official title:
An Exploratory and Open Clinical Study of Apatinib Mesylate as First-line Treatment for Advanced Esophagus Cancer.

Status Not yet recruiting

Clinical Trial Summary

An Exploratory study of Amapinib for patients with advanced esophagus cancer .

Clinical Trial Description

An Exploratory study of Amapinib for patients with advanced esophagus cancer .

Eligible are patients with advanced esophagus cancer. Apatinib (500mg) is given daily as follows:

Metastasis after primary treatment : Apatinib + yew + platinum. Local recurrence after previous surgery/radiotherapy: Apatinib alone or in combination with platinum-based chemotherapy One therapy cycle has 28 days. Tumor response is evaluated every 2 cycles. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03542422
Study type	Interventional
Source	Af?liated Hospital of North Sichuan Medical College
Contact	Daiyuan Ma
Phone	139 9088 9661
Email	mdylx@163.com
Status	Not yet recruiting
Phase	Phase 2
Start date	June 30, 2018
Completion date	May 2019

View Details